Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (381-390 of 721) with videos related to

Pageof 73
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2024
SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PETThomas A Hope, Jeremie Calais, Ajit H Goenka, et al.
Oncotarget|February 5, 2016
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experienceConstantin Lapa, Katharina Lückerath, Martina Rudelius, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 14, 2020
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaJustin Ferdinandus, Francesco Barbato, Michal Chodyla, et al.
Theranostics|January 3, 2017
[<sup>68</sup>Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [<sup>18</sup>F]FDG and laboratory valuesConstantin Lapa, Martin Schreder, Andreas Schirbel, et al.
EJNMMI Research|October 28, 2016
Impact of <sup>68</sup>Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomyChristina Bluemel, Fraenze Linke, Ken Herrmann, et al.
Clinical Nuclear Medicine|November 8, 2016
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer PatientsChristina Bluemel, Stefanie Hahner, Britta Heinze, et al.
European Journal of Radiology|April 23, 2021
Comparison of pre- and post-contrast-enhanced attenuation correction using a CAIPI-accelerated T1-weighted Dixon 3D-VIBE sequence in <sup>68</sup>Ga-DOTATOC PET/MRINils Martin Bruckmann, Maike E Lindemann, Johannes Grueneisen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
Safety and Efficacy of <i>Para</i>-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine TumorsAlexandros Moraitis, Walter Jentzen, Pedro Fragoso Costa, et al.
Theranostics|May 14, 2025
Optimizing theranostics chatbots with context-augmented large language modelsPia Koller, Christoph Clement, Albert van Eijk, et al.
Pageof 73

Showing results (381-390 of 721) with videos related to

Sort By:
Pageof 73
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2024
SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PETThomas A Hope, Jeremie Calais, Ajit H Goenka, et al.
Oncotarget|February 5, 2016
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experienceConstantin Lapa, Katharina Lückerath, Martina Rudelius, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 14, 2020
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaJustin Ferdinandus, Francesco Barbato, Michal Chodyla, et al.
Theranostics|January 3, 2017
[<sup>68</sup>Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [<sup>18</sup>F]FDG and laboratory valuesConstantin Lapa, Martin Schreder, Andreas Schirbel, et al.
EJNMMI Research|October 28, 2016
Impact of <sup>68</sup>Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomyChristina Bluemel, Fraenze Linke, Ken Herrmann, et al.
Clinical Nuclear Medicine|November 8, 2016
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer PatientsChristina Bluemel, Stefanie Hahner, Britta Heinze, et al.
European Journal of Radiology|April 23, 2021
Comparison of pre- and post-contrast-enhanced attenuation correction using a CAIPI-accelerated T1-weighted Dixon 3D-VIBE sequence in <sup>68</sup>Ga-DOTATOC PET/MRINils Martin Bruckmann, Maike E Lindemann, Johannes Grueneisen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
Safety and Efficacy of <i>Para</i>-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine TumorsAlexandros Moraitis, Walter Jentzen, Pedro Fragoso Costa, et al.
Theranostics|May 14, 2025
Optimizing theranostics chatbots with context-augmented large language modelsPia Koller, Christoph Clement, Albert van Eijk, et al.
Pageof 73